Immatics

Immatics Overview

Founded 2000
Founded
Status Private
Employees 180
Employees
Latest Deal Type Reverse Merger (Announced)
Investors 23

Immatics General Information

Description

Developer of immunotherapies designed to treat cancer. The company's immunotherapies use natural or engineered T cells to fight cancer as well as the proprietary approaches to producing Adoptive Cell Therapies are directed against targets, which will transform the current landscape of tumor therapy, providing doctors with a way to improve the length and quality of lives of cancer patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Primary Office
  • Paul-Ehrlich-Street 15
  • 72076 Tübingen
  • Germany
+49 07071 00000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Immatics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Reverse Merger 17-Mar-2020 00000 Announced Clinical Trials - General
10. Later Stage VC (Series E) 04-Oct-2017 0000 00000 Completed Clinical Trials - General
9. Grant 02-Mar-2015 000.00 00000 Completed Clinical Trials - General
8. Later Stage VC (Series D) 16-Jul-2014 000.00 00000 00000 Completed Clinical Trials - General
7. Later Stage VC (Series C) 21-Sep-2010 000.00 00000 Completed Clinical Trials - General
6. Grant 07-Jul-2008 00.000 000.00 Completed Clinical Trials - General
5. Later Stage VC (Series B) 08-Feb-2007 000.00 000.00 000.00 Completed Clinical Trials - General
4. Grant 06-Sep-2006 00000 000.00 Completed Clinical Trials - General
3. Grant 01-Aug-2005 $724K $17.6M Completed Startup
2. Early Stage VC (Series A) 11-Feb-2004 $17.6M $17.6M Completed Startup

Immatics Competitors (14)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing
Amount
NexImmune Venture Capital-Backed Gaithersburg, MD 00 000.00 00000000000 000.00
0000 000000000000 Venture Capital-Backed Houston, TX 00 00000 0000000000 0 00000
000000 Venture Capital-Backed Utrecht, Netherlands 00.000 00000000000 00.000
0000 000000000000 Formerly VC-backed Cambridge, MA 00 00000 00000000 00000
0000000000 Venture Capital-Backed Planegg, Germany 00.000 000000 0 00.000

Immatics Executive Team (18)

Name Title Board Seat Contact Info
Harpreet Singh Ph.D Co-Founder, Managing Director & Chief Executive Officer
Thomas Ulmer Managing Director & Chief Financial Officer
Toni Weinschenk Ph.D Co-Founder & Chief Technology Officer
Carsten Reinhardt Ph.D Managing Director & Chief Medical Officer
Rainer Kramer Ph.D Managing Director & Chief Business Officer

6 Former Executives

Immatics Board Members (6)

To view Immatics‘s full board member team, request access »
Name Representing Role Since
Christof Hettich Self Board Member 000 0000
Erich Schlick Wellington Partners Board Member 000 0000
Friedrich Von Bohlen Ph.D dievini Board Member 000 0000
Harald Stock Ph.D Self Board Member 000 0000
Matthias Kromayer Ph.D MIG AG Board Member 000 0000

Immatics Investors (23)

To view Immatics‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Amgen Corporation Minority 000 0000 000000 0
LSG Holdings Family Office Minority 000 0000 000000 0
NS Investments Venture Capital Minority 000 0000 000000 0
Cancer Prevention and Research Institute of Texas Government 000 0000 000000 0
AT Impf Venture Capital Minority 000 0000 000000 0

Immatics Acquisitions (1)

To view Immatics‘s complete investment and acquisition history, request access »
Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000 00000000 0000 17-Mar-2020 000000000000000000 00000 Holding Companies 00000000 00000 00.0

Ready to get started?

Request a free trial